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Introduction
ATP-sensitive potassium (KATP) channels, characterized by inhibition by intracellular ATP and activation 
by Mg-ADP, effectively link membrane excitability to metabolic state. Functional channels are composed 
of  hetero-octameric complexes: 4 Kir6.x pore forming subunits, responsible for ATP inhibition, and 4 
regulatory SURx subunits responsible for Mg-ADP activation. SUR subunits also impart sensitivity to ago-
nists (diazoxide/pinacidil) and antagonists (glibenclamide) (1). Intriguingly there are 2 pairs of  KATP genes, 
encoding SUR1 and Kir6.2 (ABCC8, KCNJ11) and SUR2 and Kir6.1 (ABCC9, KCNJ8), resulting in distinct 
subunit combinations in different cell types (2, 3), with additional structural heterogeneity provided by vari-
able splicing in SUR1 and SUR2 (1, 4, 5). Kir6.2 and SUR1 are predominantly expressed in the pancreas 
and neurons, Kir6.2 and SUR2A in cardiomyocytes, and Kir6.1 and SUR2B in vascular smooth muscle 
(6–9). KATP channels are present in the gastrointestinal (GI) tract, but these have received less attention, 
and expressed isoforms are not entirely clear (10). Here, we demonstrate first that intestinal contractility is 
reliant on Kir6.1 and SUR2 expression in smooth muscle and, secondly, that pathogenic mutations within 
ABCC9 and KCNJ8, both of  which underlie Cantú syndrome (CS), result in impaired contractility and 
motility in both small intestine and colon.
After leaving the stomach, food moves down the length of  the intestinal tract via segmented peri-
stalsis, driven by slow waves produced in the pacemaking interstitial cells of  Cajal (ICC). ICC exist in 
an electrically coupled syncytium together with smooth muscle cells (SMC) and PDGFRα+ cells, linking 
slow wave generation to SMC contraction (11). The organization of  this process is coordinated by the 
enteric nervous system (ENS), allowing for reflexive control of  movement patterns through modulation 
of  Ca2+ release in ICC and SMCs (12, 13). All 4 KATP transcripts have been identified in ICC and, while 
both diazoxide and pinacidil have been shown to elicit current in ICC in culture, it appears that freshly 
isolated colonic ICC exhibit no pinacidil-sensitive current (14–16). Functional KATP channels are clearly 
Cantú syndrome (CS), caused by gain-of-function (GOF) mutations in pore-forming (Kir6.1, KCNJ8) 
and accessory (SUR2, ABCC9) ATP-sensitive potassium (KATP) channel subunit genes, is frequently 
accompanied by gastrointestinal (GI) dysmotility, and we describe 1 CS patient who required an 
implanted intestinal irrigation system for successful stooling. We used gene-modified mice to 
assess the underlying KATP channel subunits in gut smooth muscle and to model the consequences 
of altered KATP channels in CS gut. We show that Kir6.1/SUR2 subunits underlie smooth muscle 
KATP channels throughout the small intestine and colon. Knockin mice, carrying human KCNJ8 and 
ABCC9 CS mutations in the endogenous loci, exhibited reduced intrinsic contractility throughout the 
intestine, resulting in death when weaned onto solid food in the most severely affected animals. 
Death was avoided by weaning onto a liquid gel diet, implicating intestinal insufficiency and 
bowel impaction as the underlying cause, and GI transit was normalized by treatment with the KATP 
inhibitor glibenclamide. We thus define the molecular basis of intestinal KATP channel activity, the 
mechanism by which overactivity results in GI insufficiency, and a viable approach to therapy.
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present in intestinal SMCs, providing a target for KATP to influence contraction directly (11, 16). We are 
unaware of  any definitive studies of  subunit contributions to functional channels being carried out using 
gene KO animals, even though such studies have been carried out extensively in pancreas, nervous system, 
cardiac and skeletal muscle. In this study, we first used KATP subunit–KO mice, as well as tissue-specific 
knockdown of  Kir6.1, to show that Kir6.1 and SUR2 are the major subunits underlying functionally 
relevant intestinal KATP channels in the SMCs.
Although these channels are not markedly active and do not influence contractility under basal condi-
tions, contractility is dramatically inhibited by pharmacological activation. Patients with mutations in Kir6.1 
or SUR2 that result in an increase in KATP channel function suffer from CS, characterized by congenital 
hypertrichosis, macrocephaly, coarse facial features, and complex cardiovascular features (17–20). Intestinal 
dysfunction is reported in a significant number of  CS patients, generally appearing as severe constipation or 
slow intestinal motility, as well as gastroesophageal reflux and pyloric stenosis, with ~25% of  patients requir-
ing a feeding tube as infants or young children (21). Of  the patients studied at the Washington University 
Cantú Research Clinic, one particularly dramatic example is a male subject with the common CS mutation 
SUR2[R1116H] (20, 21). This patient was born at 29 weeks gestation with significant edema, excessive 
scalp and body hair, and a patent ductus arteriosus that required surgery at 5 weeks of  age; at 7 months of  
age, this patient was found to have an enlarged heart and small pericardial effusion, as well as pulmonary 
hypertension and a history of  tracheobronchomalacia. As an infant, he was diagnosed with neuropathy of  
the GI system, including the small bowel and colon, requiring gastrostomy tube feedings. He was fitted with 
an antegrade continence enema (ACE) tube, through which he still receives nightly irrigation (1250 mL of  
saline with added bisacodyl and glycerin, infused into the colon through the ACE tube over 1 1/2 hours) 
at 14 years of  age and, without which, he develops extreme constipation due to lack of  intestinal motility.
Through analysis of  mice in which CS mutations were introduced to the equivalent loci in the mouse 
KCNJ8 and ABCC9 genes, we previously demonstrated that vascular smooth muscle hypoexcitability under-
lies the cardiovascular features of  CS (3, 22), but the multifaceted presentation in other tissues is not easily 
explained by chronic vascular dilation. Mice carrying more severe KATP gain-of-function (GOF) (homozygous 
Kir6.1[V65M], and double heterozygous Kir6.1[V65M]/SUR2[A478V]) CS mutations are associated with 
increased mortality, with death occurring around weaning (3). In these animals, we observe affected and dis-
tended bowels at the time of  death, suggesting the possibility of  GI dysfunction. We show here that even basal 
intestinal contractility and muscle tone are reduced in CS mice, in correlation with the molecular severity of  
the mutation. We further demonstrate that, in heterozygous Kir6.1[V65M] animals, reduced intestinal con-
tractility results in significantly reduced intestinal transit rate, without disruption of  intrinsic enteric neuronal 
activity. We thus identify KATP as a direct regulator of  contractility via intestinal smooth muscle itself, provid-
ing a potential future target for treatment of  CS symptoms, as well as of  broader GI dysfunction.
Results
Kir6.1- and SUR2-dependent KATP channels can influence intestinal contractility. To assess the role of  KATP 
channels in control of  intestinal contractility, we used combinations of  pharmacology and genetic 
manipulation of  KATP subunits, examining contractility in isolated intestinal segments (see Methods). 
Figure 1A shows a representative experiment on a segment from WT ileum. Similar recordings were 
obtained from duodenum, jejunum, and colon. In each case, contractions occurred rhythmically on 
top of  a steady active tension (Figure 1B). Fourier analysis revealed a dominant frequency of  0.6–0.8 
Hz in all segments, except the colon. Colonic contractions were less regular, and the dominant fre-
quency was slower (Figure 1C).
To assess the consequence of  SUR2-dependent KATP channel activation on contraction, the selective 
agonist pinacidil was added to the bath. Pinacidil caused a dose-dependent reduction in tension in all 
WT segments, with an IC50 of  about 1–3 μM in all segments (Figure 1, A and E). Although Kir6.1 has 
long been presumed to be the relevant KATP channel pore-forming subunit, prior studies have demon-
strated the presence of  both Kir6.1 and Kir6.2 transcripts in intestinal muscle (10). We therefore also 
assessed pinacidil sensitivity in gut segments from Kir6.1- (23) and Kir6.2-KO mice (24). Kir6.1-KO 
segments exhibited a marked reduction in sensitivity to pinacidil in all segments, whereas pinacidil 
sensitivity was essentially unaltered by KO of  Kir6.2, except in the colon (Figure 1, D and E). At 10 
μM, pinacidil, WT duodenum, jejunum, ileum, and colon segment relative tension was reduced to 0.24 
± 0.09, 0.14 ± 0.07, 0.07 ± 0.02, and 0.12 ± 0.04, respectively, versus 0.79 ± 0.10, 0.73 ± 0.14, 0.45 ± 
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0.06, and 0.36 ± 0.07, respectively, in Kir6.1-KO segments, and versus 0.16 ± 0.07, 0.07 ± 0.02, 0.05 ± 
0.03, and 0.26 ± 0.05, respectively, in Kir6.2 KO segments. These data confirm that Kir6.1 is the only 
relevant Kir6 subunit in mediating pinacidil-induced relaxation in the small intestine, although Kir6.2 
subunits may also play a regulatory role in the colon.
Figure 1. Kir6.1/SUR2 regulate intestinal contractility independently of pacemaker activity. (A) Representative recording of spontaneous contractions 
from WT ileum in the presence of increasing concentrations of pinacidil, followed by zero calcium (Ca) and high potassium (KCl). (B) Representative 
recordings of jejunal and colonic contractions in the absence and presence of pinacidil (above), and Fourier transform (below). (C) Dominant frequency of 
contraction at 0, 0.3, and 3 μM pinacidil in all segments, obtained from FFT analysis as in B (for duodenum, jejunum, ileum, and colon, n = 15, 14, 12, and 16, 
respectively). (D) Representative recordings of contraction in ileum segments from Kir6.1- and Kir6.2-KO mice following the same protocol as in A. (E) Pinaci-
dil-response (relative tension) relationships for duodenum, jejunum, ileum, and colon from experiments as above (for WT duodenum, jejunum, ileum, and 
colon, n = 6, 5, 6, and 5, respectively. Kir6.1-KO duodenum, jejunum, ileum, and colon; n = 4, 5, 6, and 4, respectively. Kir6.2 -KO duodenum, jejunum, ileum, 
and colon; n = 5, 8, 4, and 7, respectively). Fits are arbitrary Hill plots for illustrative purposes only. In the KO animals, the pedestal may not be accurate.
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Functional Kir6.1 and SUR2 are present in intestinal smooth muscle. Previous analyses of   KATP subunit 
expression have identified Kir6.1 and SUR2 in both intestinal SMCs and in the ICC (14–16). Importantly, 
the dominant frequency of  contraction was unaffected by pinacidil; even as amplitude of  contractions 
was reduced, the frequency was essentially unaffected (Figure 1, B and C). This suggests that the pinacidil 
action is on the SMCs, rather than the ICC. Consistent with this finding, we observed prominent mRNA 
expression of  both Kir6.1 and SUR2B in intestinal smooth muscle but not the mucosa, throughout the 
small intestine and colon (Figure 2A).
Smooth muscle myosin heavy chain (SMMHC) is a ubiquitous marker of  SMC lineage, and its promot-
er has been used to specifically target smooth muscle in many tissues, including the intestine (25, 26). We 
used mice expressing dominant-negative (DN) Kir6.1[AAA] subunits (SM-DN), under control of  smooth 
muscle–specific SMMHC-Cre (27, 28), to specifically disrupt smooth muscle KATP  channels (Figure 2, B and 
C). With the exception of  the colon, this resulted in significant reduction of  pinacidil sensitivity; duodenal, 
jejunal, and ileal segments were essentially insensitive to low (i.e., KATP-specific) concentrations below 10 
μM. Interestingly, while the pinacidil-insensitive component of  WT contractility gradually increased along 
the intestines from proximal to distal, the pinacidil-insensitive component in SM-DN intestines gradually 
decreased to the same level, such that both WT and SM-DN colon exhibited similar levels of  pinacidil 
insensitivity. This suggests that the potency of  smooth muscle KATP activation gradually decreases from 
proximal to distal. We additionally confirmed the presence of  KATP channels in intestinal SMCs through 
whole-cell patch-clamp recordings (Figure 2D) using a previously established protocol (14): in WT, small 
K currents were present under basal conditions at –70 mV, but large currents were induced by subsequent 
pinacidil addition, and these currents were inhibited by further addition of  10 μM glibenclamide. Together, 
these results demonstrate that, at least in the small intestine, the functionally relevant KATP channels are in 
the smooth muscle itself, but they suggest that this may not be the case in the colon.
GOF CS mutations result in reduced basal contractility in the small intestine. Having determined that 
Kir6.1/SUR2-dependent KATP channels are functionally relevant to intestinal contractility, we turned our 
attention to the potential pathological impacts of  KATP GOF in CS. SUR2 and Kir6.1 mutations cause 
essentially the same CS features, and we previously generated 2 mouse models of  CS, in which human 
CS mutations (A478V in SUR2 and V65M in Kir6.1) were knocked in to the mouse genome using 
CRISPR/Cas9 (3, 17). Both animals reiterate key cardiovascular features of  CS, including low blood 
pressure and enlarged hearts (3, 22), but the impact on the GI system has not been assessed.
The effects of  the introduced mutations on KATP channel function were determined using patch-clamp 
electrophysiology, as above. Basal K+ currents were markedly higher than WT in SUR2AV/AV, and more so in 
Kir6.1WT/VM myocytes (Figure 2D). Maximum pinacidil-activated currents were also significantly higher than 
WT in Kir6.1WT/VM. Subsequent application of  the KATP channel inhibitor glibenclamide markedly reduced 
the pinacidil-activated conductance in WT and SUR2AV/AV myocytes, but it was less effective in Kir6.1WT/VM 
(Figure 2D), potentially reflecting reduced glibenclamide sensitivity of  Kir6.1[V65M] channels (29).
Negligible basal K conductance in WT myocytes suggests that KATP activity will not normally play 
any prominent role under basal conditions. Accordingly, in WT intestinal segments, application of  a high 
concentration of  the KATP channel inhibitor glibenclamide (10 μM) had no obvious contraction-enhancing 
effects under basal conditions (Figure 3, A and B). In contrast, the much larger basal K+ conductance 
in CS myocytes could be expected to reduce even basal contractility. Indeed, glibenclamide caused a 
marked increase in both the pulsatile contraction amplitude and the steady tension in the jejunum, ileum, 
and colon of  both heterozygous SUR2WT/AV, homozygous SUR2AV/AV, and heterozygous Kir6.1WT/VM mice 
(Figure 3, A and B). The effect of  glibenclamide increased with the expected severity of  the molecular 
GOF (3) — from SUR2WT/AV to SUR2AV/AV to Kir6.1WT/VM (Figure 3B).
These data demonstrate a decreased intrinsic basal contractility in CS small intestine and colon, due to 
increased basal KATP channel activity that can be inhibited by glibenclamide. Basal KATP conductance is expect-
ed to cause hyperpolarization of the muscle and suppression of the slow electrical waves that drive the eleva-
tion of intracellular [Ca2+] that underlies contractile activity. To assess this directly, we measured membrane 
potentials in intestinal segments using impaled sharp electrodes (Figure 3, C–E). In WT tissue, we observed 
slow waves with average amplitude of 13.7 ± 1.3 mV, and in mutant mice, there was a progressive decrease in 
amplitude in SUR2AV/AV and Kir6.1WT/VM. In addition to this reduction in slow-wave amplitude, we observed 
an increase in the maximum hyperpolarization from about –50 mV in WT to about –65 mV in Kir6.1WT/VM but 
with no obvious decrease in the frequency of oscillations (Figure 3; 0.50 ± 0.01 per second for WT, 0.43 ± 0.07 
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Figure 2. KATP action on intestine contractility is through smooth muscle. (A) RT-PCR shows expression of both Kir6.1 and SUR2B subunits specifically in the 
muscular layer of all segments of the GI tract. mRNA expression from WT/AV, AV/AV, and WT/VM were also assessed and showed consistent expression across 
all segments. WT/VM expression is shown here. (B) Representative recordings of spontaneous contractions in jejunum and colon from animals expressing a 
dominant-negative (Kir6.2[AAA]) construct specifically in smooth muscle (SM-DN), following the protocol shown in Figure 1A. (C) Relative tension in the presence 
of maximum (10 μM) pinacidil relative to the tension basal conditions (from experiments in B and Figure 1A). Significance was determined with Welch t test 
comparing SM-DN with WT for each segment. WT duodenum, jejunum, ileum, and colon; n = 5, 8, 4, and 5, respectively. SM-DN duodenum, jejunum, ileum, 
and colon; n = 4, 4, 3, and 3, respectively. (D) Representative whole-cell patch-clamp recordings and mean K+ current density (initial current in high Na+ solution 
subtracted), in isolated intestinal smooth muscle from WT and Cantú mice. Current density in high K+ solution is higher in SUR2AV/AV and Kir6.1WT/VM, relative to WT, 
demonstrating GOF. Glibenclamide inhibited pinacidil-activated current in all genotypes, although inhibition was incomplete in Kir6.1WT/VM (For WT n = 10 cells from 
5 mice, SUR2AV/WT n = 4 cells from 1 mouse, SUR2AV/AV n = 7 cells from 2 mice, Kir6.1WT/VM n = 9 cells from 2 mice). Significance was determined by 1-way ANOVA and 
post hoc Tukey’s test for pairwise comparison. Data shown as mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001).
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per second for SUR2AV/AV, 0.44 ± 0.07 per second for Kir6.1WT/VM). This is consistent with the consensus that 
slow waves are initiated in the ICC, which lack functional KATP (14), and are then conducted to and through 
the SMC syncytium.
CS mutations reduce colonic contractility through direct inhibition of  smooth muscle. A key component of  normal 
GI transit is tonic suppressive control of  colonic motility by the colonic migrating motor complex (CMMC), 
in turn controlled by the ENS (12, 30). Although neither Kir6.1 nor SUR2 is prominently expressed in neu-
rons, this raises the possibility that reduced colonic contractility in CS tissues might be a consequence of  
altered neuronal control rather than a direct smooth muscle inhibition. By inhibition of  neuronal Na+ chan-
nels, tetrodotoxin (TTX) suppresses enteric neurotransmission and increases colonic contractility (31). TTX 
(1 μM) increased tension similarly in both WT and Kir6.1WT/VM colonic segments (Figure 4, A and B). Sub-
sequent application of  glibenclamide, in the continued presence of  TTX, still causes increased tension in 
Kir6.1WT/VM, but not in WT, colonic segments (Figure 4, A and C). This indicates that the excitatory effect 
of  glibenclamide on colonic contractility is present even when enteric neuronal activity is suppressed, further 
indicating that the effect is reliant on inhibition of  basally active smooth muscle KATP in the CS colon.
SUR2 and Kir6.1 mutants have different effects on pinacidil sensitivity. While glibenclamide treatment 
demonstrates that all CS mutant intestinal segments have reduced basal contractility, mutant CS segments 
Figure 3. KATP GOF mutations in smooth muscle cause hyperpolarization and reduced basal contractility. (A) Representative records of basal tension in 
WT (black), SUR2AV/AV (red), and Kir6.1WT/VM (blue) ileal segments before (basal) and after application of glibenclamide (at arrow). (B) Tension in gliben-
clamide relative to basal, from experiments as in A. Significance was determined by 1-way ANOVA and post hoc Tukey’s test for pairwise comparison. 
WT duodenum, jejunum, ileum and colon; n = 6, 7, 7, and 4, respectively. SUR2AV/WT duodenum, jejunum, ileum, and colon; n = 5, 4, 7, and 8, respective-
ly. SUR2AV/AV duodenum, jejunum, ileum, and colon; n = 4, 8, 8, and 9, respectively. Kir6.1WT/VM duodenum, jejunum, ileum, and colon; n = 5, 8, 11, and 6, 
respectively. (C) Representative recordings of electrical activity in WT, SUR2AV/AV, and Kir6.1WT/VM intestinal muscle segments, measured using impalement 
electrodes. (D) Slow wave amplitude measured from maximum hyperpolarized potential to maximum nonspiking plateau potential in WT, SUR2AV/AV, 
and Kir6.1WT/VM muscle from experiments as in A. (E) Resting membrane potential (maximum hyperpolarized potential) in WT, SUR2AV/AV, and Kir6.1WT/VM 
muscle. For D and E, n = 7 for WT, n = 4 for SUR2AV/AV, and n = for Kir6.1WT/VM. For each segment, significance was determined by 1-way ANOVA and post hoc 
Dunnett’s test, comparing each genotype with WT. Data are shown as mean ± SEM (*P < 0.05, ***P < 0.001).
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also show enhanced sensitivity to pinacidil. Reflecting a higher “activatability” of  the mutant channels, this 
is more pronounced in SUR2AV/AV versus SUR2WT/AV segments and still more pronounced in Kir6.1WT/VM 
segments, again paralleling the effect of  the severity of  the mutation on nucleotide sensitivity (3) (Figure 
5, A–D). Interestingly, in SUR2WT/VM and more so in SUR2AV/AV segments, there was a marked pedestal of  
activity even at saturating pinacidil concentrations, an effect that was absent in Kir6.1WT/VM segments (Fig-
ure 5E). Although further experiments would be necessary, this suggests the possibility that some compen-
satory effect, either a reduction in total SUR2 (and hence in KATP channel density) or perhaps an increase 
of  an excitatory current, is present in the SUR2[A478V] tissues.
CS V65M mutation markedly reduces GI transit in heterozygous animals and is lethal in homozygous ani-
mals. We previously reported that, although life expectancy was not markedly affected in heterozygous 
SUR2WT/AV or Kir6.1WT/VM animals, nor in homozygous SUR2AV/AV, more severely affected homozy-
gous Kir6.1VM/VM and double-heterozygous SUR2WT/AV/Kir6.1WT/VM animals died around weaning (3), 
precluding further detailed study of  phenotype. Anecdotally, at necropsy, we observe that Kir6.1VM/VM 
intestines are typically filled with solid matter. Previous studies have recognized pseudo-obstruction 
of  the intestines caused by loss of  smooth muscle function (32–35), and we hypothesize that, in these 
animals, this is severe enough to preclude food transit through the gut following transition from milk 
to solid food. We have now attempted weaning homozygous V65M onto liquid gel diets (with the same 
nutritional composition as normal solid chow). While this does not completely abrogate the lethality, 
we do observe a striking increase in the number of  Kir6.1VM/VM mice surviving past weaning (Figure 
6A), suggesting that inability to move solid food is indeed a direct cause of  almost uniform lethality in 
the most severely affected CS mice.
Our isolated tissue data indicate a markedly reduced basal contractility in CS intestinal muscles 
(Figure 4). In vivo, this might be expected to reduce the rate of  transit of  food through the intestines. 
To test this directly, we administered a bolus of  FITC–labeled dextran by oral gavage and determined 
the distribution through the gut 90 minutes later. Kir6.1VM/WT mice exhibited significantly slowed tran-
sit, with the geometric center shifting from segment 10 in WT mice back to segment 7 in Kir6.1VM/WT 
mice (Figure 6, B and C). To directly assess the impact of  KATP activation on transit, we treated WT 
mice with a high dose of  pinacidil (1 mg/mouse, i.p.) 30 minutes before dextran administration. Fol-
lowing pinacidil treatment, we observed an even greater slowing of  transit, with the geometric center 
shifting to segment 3 (Figure 6, B and C).
Pharmacological inhibition of  overactive KATP can reverse transit defect in het V65M animals. Finally, we sought 
to determine whether these transit deficits might be mitigated by pharmacological inhibition of  KATP (22). 
We treated mice with high doses of  glibenclamide (0.25 mg/mouse, i.p.), — 1 dose given 24 hours before 
assay and a second dose delivered immediately following FITC-dextran administration. Strikingly, gliben-
clamide had no significant effect on transit in WT animals but essentially completely normalized the geo-
metric center in Kir6.1WT/VM animals (Figure 6, A and B), demonstrating the potential of  such an approach 
as treatment for GI dysmotility in CS.
Discussion
The role of  KATP electrical regulation of  GI motility. GI motility arises from the coordinated activity of  the 
intestinal SMCs, ICC, and PDGFRα+ cell (SIP) syncytium, the activity of  which is in turn modulated 
by the ENS, allowing for the coordination of  motility patterns. In this study, we have explored the 
role that KATP channels play in GI motility, confirming that KATP is present and functionally relevant in 
SMCs of  the small intestine and colon, and demonstrating that GOF mutations in these channels can 
result in significant GI dysmotility.
The presence and identity of  KATP channels in various cell types of  the SIP syncytium have been 
reported previously, but their specific identity and the localization of  relevant function has been unclear. 
Colonic SMCs have been shown to exhibit pinacidil- and ADP-activated currents, but ascribed to dif-
ferent Kir6 subunits in different studies (14, 36). While ICC in culture have been shown to express 
Kir6.1 and SUR2B in the colon but Kir6.2 and SUR2B in the small intestine, freshly isolated colonic 
ICC exhibit expression of  both Kir6 isoforms but do not appear to have any KATP activity (14, 15). 
Consistent with them also having no relevant effect on ICC pacemaker activity, we show that activa-
tion of  KATP by pinacidil dramatically reduces contractility of  intestinal segments, but without altering 
the frequency of  contraction. Previous studies have demonstrated that control of  vascular tone by KATP 
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is through Kir6.1/SUR2B-dependent channels in SMCs (3), and in this study, we confirm that these 
same channels are also acting through the smooth muscle in the intestine. Using gene KO animals, we 
first show that channels composed of  Kir6.1, but not Kir6.2, are predominant in regulation of  contrac-
tility throughout the intestines. This is demonstrated by dose-dependent pinacidil inhibition, which 
indicates involvement of  SUR2 and which is significantly reduced in the absence of  Kir6.1 but not 
Kir6.2. Our results are consistent with the recent observation that Kir6.1, but not Kir6.2, is expressed 
in colonic smooth muscle (14) and suggest that this may be the case throughout the intestinal tract. 
They also argue that smooth muscle is the functionally relevant location of  KATP throughout. First, 
using whole-cell patch-clamp recordings in ileal SMCs, we show the presence of  pinacidil-activated 
currents that are inhibited by glibenclamide, indicating the presence of  functional KATP in these cells. 
Second, in mice expressing Kir6.1 or SUR2 GOF mutants, we observe a reduction in tone and reduced 
amplitude of  contractions, but the frequency of  contractions remains unaltered, suggesting that ICC 
pacing is unaffected. Finally, expression of  DN Kir6.1(AAA) in smooth muscle (which will suppress 
both Kir6.2- and Kir6.1-dependent channels; ref. 25) significantly reduces the effect of  pinacidil — to 
the level seen in Kir6.1-KO animals — throughout the small intestine. It is important to note that, even 
in the absence of  Kir6.1/SUR2-dependent currents, there remains a low-affinity and incomplete sensi-
tivity to pinacidil, an effect that is especially prominent in the colon. While the most likely explanation 
is a nonspecific drug action beyond surface KATP channels, it remains conceivable that there is a source 
of  (presumably Kir6.2-dependent) KATP  activity in tissues other than smooth muscle that nevertheless 
can have an effect on colonic contractility.
While most inputs from enteric neurotransmitters may be unlikely to be mediated by changes in 
the open probability of  KATP channels, some bioactive mediators, including vasoactive intestinal peptide 
Figure 4. KATP GOF mutations in smooth muscle, not enteric neurons, reduce basal contractility. (A) Response to tetrodotoxin (TTX, 1 μM) followed by 1 
μM glibenclamide in WT and Kir6.1WT/VM colon segments. Abolition of neuronal activity with glibenclamide increased tension in both genotypes. Gliben-
clamide caused large increase in Kir6.1WT/VM segments even after abolition of neuronal activity. (B) TTX induced contractions in all colonic segments of WT 
and Kir6.1WT/VM segments. (C) Only Kir6.1WT/VM segments exhibited a significant increase in tension in response to glibenclamide. WT, n = 6; Kir6.1WT/VM, n = 7. 
Each segment was compared with WT using Welch t test. Data shown as mean ± SEM (*P < 0.05, **P < 0.01).
 
9insight.jci.org   https://doi.org/10.1172/jci.insight.141443
R E S E A R C H  A R T I C L E
(VIP) (37, 38), pituitary adenylate cyclase activating polypeptide (PACAP) (39), and prostaglandins (38, 
40), couple through Gs and enhanced cAMP, which can in turn activate KATP. Thus, while our results 
argue that there is little effect of  WT smooth muscle KATP on intestinal contractility under our basal 
experimental conditions, it is important to note that they do not preclude a role for humorally mediated 
KATP activation in normal postprandial motility or a role for an enhanced effect in CS.
Figure 5. KATP GOF mutations do not affect intestinal contractile frequency but do alter pinacidil response. (A) Representative recordings of tension in WT 
(black), SUR2AV/AV (red), and Kir6.1WT/VM (blue) ileal segments in the absence and presence of pinacidil, following the protocol shown in Figure 1. (B) Fourier anal-
ysis reveals no significant effect of CS mutations on contractile frequency in any segments of the small intestine or the colon (WT duodenum, jejunum, ileum, 
and colon; n = 13, 17, 19, and 12, respectively. SUR2AV/WT duodenum, jejunum, ileum, and colon; n = 4, 9, 7, and 10, respectively. SUR2AV/AV duodenum, jejunum, 
ileum, and colon; n = 10, 12, 15, and 9, respectively. Kir6.1WT/VM duodenum, jejunum, ileum, and colon; n = 10, 9, 13, and 11, respectively). (C) Pinacidil-response 
(relative tension) relationships for WT (black), SUR2AV/AV (red), and Kir6.1WT/VM (blue) duodenum, jejunum, and ileum, from experiments as above. SUR2WT/AV and 
SUR2AV/AV exhibit an increase in pinacidil-insensitive component of contraction, but Kir6.1WT/VM do not. For illustrative purposes, average dose-responses are fit 
with single sigmoidal curves. (D and E) Half maximal inhibitory concentration in CS (D), and pinacidil-insensitive contraction as a fraction of the contraction in 
zero pinacidil (E), for SUR2WT/AV (WT/AV) and SUR2AV/AV (AV/AV) segments. For C–E, WT duodenum, jejunum, ileum, and colon; n = 6, 5, 5, and 5, respectively. 
SUR2AV/WT duodenum, jejunum, ileum, and colon; n = 3, 3, 5, and 3, respectively. SUR2AV/AV duodenum, jejunum, ileum, and colon; n = 5, 6, 4, and 4, respectively. 
Kir6.1WT/VM duodenum, jejunum, ileum, and colon; n = 5, 3, 5, and 4 respectively). For all panels, significance was determined by 1-way ANOVA for each segment 
and post hoc Dunnett’s test, comparing each genotype with WT. Data are shown as mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001).
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KATP-dependent GI dysmotility in CS. GOF mutations in either Kir6.1 or SUR2 underlie human CS 
(OMIM #239850) (41–43). While CS has principally been characterized by hypertrichosis, distinct 
facial appearance, cardiomegaly, and other cardiovascular features, GI dysfunction is also prominent 
in CS patients, with symptoms ranging from mild to very severe constipation (43). As we now report, 
in one particularly extreme example, the patient has been unable to defecate, resulting in years of  total 
parenteral nutrition, followed by surgical implantation of  an irrigation system, and even then requiring 
daily massage to achieve defecation. Mice carrying mutations analogous to CS-causing mutations in 
humans (Kir6.1[V65M] and SUR2[A478V]) reiterate the cardiomegaly and other vascular features of  
human CS (3), but we do not observe obvious GI problems, except in the more severely affected homo-
zygous Kir6.1VM/VM or double-heterozygous SUR2WT/AV/Kir6.1WT/VM (3). As we now show, hetereozy-
gous Kir6.1WT/VM animals exhibit marked inhibition of  intestinal transit, and homozygous Kir6.1VM/VM 
die around weaning, unless weaned onto a liquid gel diet.
We also show that, in WT intestinal segments, basal contractility — at least under experimental 
conditions — reveals no obvious KATP channel activity. This is in contrast to vascular muscle, where 
we have good evidence for KATP channels playing a role even in basal tone in WT animals, such that 
KATP KO results in a hypertensive phenotype (7, 23, 44), and essentially all CS patients (21), as well as 
all CS mice (3), exhibit low vascular resistance and consequently enlarged hearts (22). While CS mice 
Figure 6. KATP GOF animals exhibit impaired transit, which can be corrected with glibenclamide. (A) Kaplan-Meier survival curves for homozygous 
Kir6.1VM/VM animals when weaned onto solid food. There is significant mortality around the time of weaning onto solid food (gray line), but survival is 
improved when weaned onto liquid diet. (B) The distribution of FITC-dextran in equal length segments of the GI tract from stomach (Sto), through the 
small bowel (SB), the cecum (Cec), and colon (Col) at 90 minutes following oral gavage in WT and Kir6.1WT/VM animals, with or without glibenclamide or 
pinacidil treatment. (C) The geometric center of FITC-dextran load from individual experiments as in B. For B and C, n = 15 for WT, n = 10 for WT + gliben-
clamide (Glib), n = 5 for WT + pinacidil (Pin), n = 15 for Kir6.1WT/VM, and n = 10 for Kir6.1WT/VM + Glib. Significance was determined by 1-way ANOVA and post 
hoc Tukey’s test for pairwise comparison. Data shown as mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001).
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exhibit a clear increase in severity of  both cardiovascular and GI pathology that correlates with the 
severity of  the molecular defect (from SUR2[A478V] to Kir6.1[V65M] and from hetero- to homozygous 
presentation), GI problems in human CS are quite variable, and at this juncture, we cannot discern a 
clear molecular mutation disease severity correlation. One potential reason for a threshold effect of  CS 
mutations on GI function (e.g., that some patients experience mild or no dysmotility, whereas others, 
such as we describe here, experience very severe problems — as is reiterated in the V65M CS mice) 
may depend on whether the mutational effect is sufficient to cross the threshold for reducing basal 
contractility and, hence, slowing down motility or not. Clearly, in some CS patients (and reiterated in 
mice with sufficiently marked mutagenic effect), the resultant GI dysmotility is severe, and a therapeutic 
remedy is warranted. Glibenclamide or other inhibitors of  KATP channels show promise as therapeutic 
agents to directly treat CS pathology in the cardiovascular system (22, 45). As we show here, acute treat-
ment with glibenclamide also causes striking reversal of  the transit deficiency in Kir6.1WT/VM animals, 
dramatically illustrating the potential for glibenclamide treatment of  CS GI dysmotility and raising 
the further possibility that such treatments might be effective in any other GI dysmotilities resulting 
from decreased smooth muscle excitability. In principle, since Kir6.1/SUR2B-dependent channel activ-
ity will be enhanced in all relevant tissues, glibenclamide or another inhibitor might be expected to 
improve outcome in all such tissues in CS. However, it is worth noting that SUR2 is also implicated 
in the myocardial transition from glycolytic to oxidative metabolism that occurs during adaptation to 
postnatal life (46) and that SUR2-deleted cardiomyocytes exhibit enhanced glucose uptake (47), sug-
gesting caution regarding potential metabolic consequences of  SUR2 inhibition. Moreover, as has been 
discussed extensively elsewhere (48–52), none of  the available KATP channel inhibitors are specific for 
these isoforms, and actions on Kir6.2/SUR1-dependent channels could lead to serious complications. 
Potentially the most dangerous unwonted effect is lowering of  blood sugar levels as a result of  action on 
pancreatic Kir6.2/SUR1-dependent channels. While this does not appear to be a significant issue in CS 
mice (22), this may not be the case in human CS, and there remains a need for subunit-specific agents.
Conclusions. Kir6.1- and SUR2-dependent KATP channels are expressed and functional in intestinal 
smooth muscle, and they can influence contractility throughout the intestine. Mutations associated with 
CS, which result in a GOF of  these KATP channels, reduce smooth muscle contractility throughout the 
intestinal tract. This reduced contractility is sufficient to disrupt intestinal transit, and in the most severe 
cases, it can cause significant morbidity, explaining GI problems in CS patients (3). The KATP inhibitor 
glibenclamide, which reverses key cardiovascular features of  CS, can also restore GI transit rate in 
experimental CS. This suggests the exciting and obvious potential for their use to offer relief  from the 
GI symptoms of  CS, and possibly from other GI dysmotilities that may result from decreased smooth 
muscle excitability.
Methods
Mouse models. Kir6.1-KO mice, generated by deletion of  part of  intron 2 and exon 3 of  the Kcnj8 gene 
that includes the pore-forming region of  the channel (23), were a gift from Susumu Seino (Chiba Univer-
sity, Chiba, Japan). DN Kir6.1[AAA] was expressed in an inducible, tissue-specific manner by crossing 
Tg[CX1-EGFP-Kir6.1(AAA)] (Kir6.1[AAA]) mice (25) (a gift from William Coetzee, New York Uni-
versity, New York, New York, USA) with transgenic mice (SM-Cre) that express inducible Cre recom-
binase (CreERT2) driven by the SMMHC promoter (53). Eight-week-old mice were treated with serial 
tamoxifen injections (1 injection of  50 μg/g body weight per day for 5 days) to induce DN Kir6.1[AAA] 
expression, and experiments were performed 4 weeks after induction. Generation of  Cantú mice using 
CRISPR/Cas9 genome editing was previously reported (3). Briefly, KCNJ8 (c.193G>A/195A>G) and 
ABCC9 (c.1427C>T) mutations were introduced to mimic human CS Kir6.1[V65M] and SUR2[A487V] 
mutations, respectively. Heterozygous Kir6.1[V65M] (Kir6.1WT/VM) and SUR2[A478V] (SUR2WT/AV) 
mice mimic the autosomal-dominant context observed in patients. SUR2WT/AV mice and Kir6.1WT/VM 
mice were each in-crossed to generate homozygous mutant mice (SUR2AV/AV). Male and female mice 
were used for all experimental groups. Littermate WT mice were used for all comparisons.
Isometric tension recordings. Adult male and female mice were euthanized by overdose of 2.5% Avertin fol-
lowed by cervical dislocation. Laparotomy was then performed, and the whole intestine was excised and placed 
into ice cold Krebs-Ringer solution containing (in mM) NaCl 120, KCl 5.9, CaCl2 dihydrate 2.5, MgSO4 1.2, 
NaH2PO4 1.2, NaHCO3 15.5, and glucose 11.5. The pH of the solution was adjusted to 7.4 using HCl/NaOH. 
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All chemicals were obtained from Sigma-Aldrich. A total of 1–2 cm intestinal segments was cut from the duo-
denum, jejunum, ileum, and colon. Adipose and mesentery tissue were carefully removed using micro scissors, 
and feces were flushed out using Krebs-Ringer solution. Intestinal segments were tied to metal brackets on both 
ends using 4-0 silk surgical suture and mounted in individual organ baths containing 25 mL Krebs-Ringer solu-
tion bubbled with 95% O2/5% CO2 at 37°C, to a force transducer for isometric tension recording. Tension was 
adjusted to ~1.0 g. Baseline tone was then typically relaxed to a stable ~0.5 g, and contraction amplitude was 
increased to a stable level, over a stabilization period of 15–45 minutes. Unless otherwise noted, the standard 
experimental protocol involved addition of pinacidil (0.01–30 μM) by serial additions to the bath solution at 4–5 
minute intervals. The bath solution was then twice replaced with modified Krebs-Ringer solution without calci-
um (in mM) NaCl 120, KCl 5.9, MgSO4 1.2, NaH2PO4 1.2, NaHCO3 15.5, glucose 11.5, EGTA 4. The intes-
tinal segments were left to recover in the modified zero Ca Krebs-Ringer solution for 15–20 minutes to achieve 
minimal tension. Maximal tension was then assessed by replacement of bath solution with a modified high [K+] 
Krebs-Ringer solution (in mM) KCL 126, CaCl2 2.5, MgS04 1.2, NaH2PO4 1.2, NaHCO3 15.5, glucose 11.5. 
Tension in each condition was calculated by averaging the tension during the final 1 minute before the following 
treatment, with the exception of the high K response, for which the maximum value was taken. Relative tension 
is defined by the following equation:
Relative tension = (tension – tension in 0 Ca)/(maximal tension in high K – tension in 0 Ca).
Tension recording was obtained using AdInstruments Octal Bridge Amp, PowerLab 8/30, and Lab-
Chart 7 and recorded at a 20 Hz.
Contractile frequency was assessed by fast Fourier transform (FFT) of  the tension signal during the 
final 1 minute in control and pinacidil conditions, using the Fourier analysis tool in Microsoft Excel.
Intestinal transit times. Intestinal transit was determined as in previously published studies (54, 55). A 
total of  200 μL of  a 2.5 mg/mL nonabsorbable 70 kDa fluorescein isothiocyanate – labeled dextran (FD70) 
solution — was administered by oral gavage. After 90 minutes, the animals were anesthetized with iso-
flourane and sacrificed. The GI tract was removed and divided into 15 segments (the stomach, 10 equal 
segments of  the small intestine, the caecum, and 3 equal sized segments of  the colon). The intraluminal 
contents were flushed out of  each segment with 1 mL of  PBS and collected. The samples were centrifuged, 
and the supernatant was assessed fluorometrically for concentration of  FD70. Transit was determined by 
calculation of  the geometric center of  the distribution of  FD70 (Ʃ for concentration signal in each segment 
× segment number)/100).
Colonic transit was determined using a glass bead expulsion assay. A glass bead (3 mm) was inserted 2 
cm into the colon of  a mouse after 12 hours of  fasting. Expulsion time was measured for each mouse, and 
the average for each genotype was reported.
Microelectrode recordings. Intestinal segments were isolated as described above. Intact segments were 
stretched and pinned to the sylgard base of  a tissue bath to prevent excessive movement and were perfused 
with Krebs-Ringer solution, maintained at 37°C, and continuously bubbled with 95% O2/5%CO2. The tis-
sue was impaled with thin glass microelectrodes of  10–20 MΩ resistance (when filled with 3 mM KCl), and 
the membrane potential was digitized by a Power 1401 A/D converter and recorded via PClamp. Record-
ings were taken when a stable resting membrane potential or stable oscillating potentials were observed. 
Reported membrane potential was determined by averaging minimum potential in 3–5 slow waves, and 
amplitude — measured from trough to peak — was averaged across multiple slow waves.
Patch-clamp electrophysiology. Adult mice were anesthetized with 2.5% avertin (10 mL/kg, i.p.; Milli-
poreSigma) and cervical dislocation was performed. The whole intestine was removed, from duodenum 
to rectum. Extraneous tissue was removed, and the small ileal segment was removed, segmented, and 
placed in M199 cell media (1× M199, 26 mM NaHCoO3, 2 mM glutamine, 1% penicillin-streptomycin, 
10% FBS). The tunica muscularis was peeled away along the deep muscular plexus margin, cut into small 
pieces, and placed in dissociation solution A (134 mM NaCl, 3 mM KCl, 5 mM Taurine, 5 mM EDTA, 2 
mM MgCl2, 10 mM HEPES). Tissue was then spun down, the supernatant was removed, and dissociation 
solution A with 1 mg/mL trypsin was added, followed by 15 minute incubation at 37°C. After 15 minutes, 
this solution was replaced with fresh dissociation solution A plus 1 mg/mL trypsin and incubated for fur-
ther 30 minutes at 37°C. The tissue was briefly centrifuged, and the supernatant was removed and replaced 
by dissociation solution B (134 mM NaCl, containing 3 mg/mL collagenase and 1 mg/mL BSA) and 
then further incubated for 33 minutes at 37°C. After incubation, the mixture was shaken at 800 rpm for 2 
minutes, and the cell suspension was removed with effort made to limit the intact debris, layered on top of  
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20% (w/v) Ficoll, and centrifuged at 20g for 15 minutes at room temperature. The cell band located at the 
interface was removed, and M199 media was added. Cells were resuspended in fresh M199 and plated on 
glass coverslips for recording.
Whole-cell KATP currents were recorded using an Axopatch 200B amplifier and Digidata 1200 (Molec-
ular Devices), following a previously published protocol for characterization of  Kir6.1/SUR2 in SM cells 
(3). Recordings were sampled at 3 kHz and filtered at 1 kHz. Currents were initially measured at a holding 
potential of  –70 mV in a high-Na+ bath solution containing (in mM) 120 NaCl, 6 KCl, 2.5 CaCl2, 1.2 
MgCl2, 10 HEPES, and 12 glucose, with pH adjusted to 7.4 with NaOH before switching to a high-K
+ bath 
solution (130 KCl, 2.5 CaCl2, 1.2 MgCl2, 10 HEPES, and 12 glucose, with pH adjusted to 7.4 with KOH) 
in the absence and presence of  pinacidil and glibenclamide as indicated. The pipette solution contained (in 
mM) 110 potassium aspartate, 30 KCl, 10 NaCl, 1 MgCl2, 10 HEPES, 0.5 CaCl2, 4 K2HPO4, and 5 EGTA, 
with pH adjusted to 7.2 with KOH.
Statistics. Statistical significance was determined using the 2-way Welch t test or 1-way ANOVA fol-
lowed by post hoc Tukey’s test or Dunnett’s test, as appropriate, and indicated in figure legends. Welch test 
was performed using Microsoft Excel. ANOVA and Tukey’s test were performed using R. Dunnett’s test 
was performed using DescTools package in R. Unless otherwise noted, data are presented as mean ± SEM. 
P < 0.05 was considered significance and P values were denoted as *P < 0.05, **P < 0.01, ***P < 0.001).
Study approval. All studies were performed in compliance with the standards for the care and use of  
animal subjects defined in Guide for the Care and Use of  Laboratory Animals (National Academies Press, 2011) 
and were reviewed and approved by the Washington University IACUC.
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